Nezu M, Souma T, Yu L, Suzuki T, Saigusa D, Ito S, Suzuki N*, Yamamoto M*.

Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression.

Kidney Int 2017 Feb;91(2):387-401. doi: 10.1016/j.kint.2016.08.023.

Press release  Press release 

Hirano I, Suzuki N, Yamazaki S, Sekine H, Minegishi N, Shimizu R, Yamamoto M.

Renal anemia model mouse established by transgenic rescue with erythropoietin gene lacking kidney-specific regulatory elements.

Mol Cell Biol 2017 Feb 1;37(4). pii: e00451-16. doi: 10.1128/MCB.00451-16. 

Nezu M, Souma T, Yu L, Sekine H, Takahashi N, Wei AZ, Ito S, Fukamizu A,

Zsengeller ZK, Nakamura T, Hozawa A, Karumanchi SA, Suzuki N*, Yamamoto M*

Nrf2 inactivation enhances placental angiogenesis in a preeclampsia mouse model and improves maternal and fetal outcomes.

Sci Signal. 2017 May 16;10(479). pii: eaam5711. doi: 10.1126/scisignal.aam5711.

Press release

Suzuki N*, Gradin K, Poellinger L, Yamamoto M.

Regulation of hypoxia-inducible gene expression after HIF activation.

Exp Cell Res 2017 Mar 9. pii: S0014-4827(17)30120-9. doi: 10.1016/j.yexcr.2017.03.013. [Epub ahead of print] PubMed PMID: 28286304.

 Nezu M, Suzuki N*, Yamamoto M.

Targeting the KEAP1-NRF2 system to prevent kidney disease progression.

Am J Nephrol 2017;45:473-483 (DOI:10.1159/000475890)

Norio Suzuki, Ikuo Hirano, Aina Fukuda, Sakae Saito, Ken-ichiro Miyauchi, Hiroki Sekine, Masayuki Yamamoto.

"Roles of renal erythropoietin-producing (REP) cells in hypoxia-inducible erythropoiesis"

Keystone Symposium on Adaptations to Hypoxia in Physiology and Disease, Whistler, British Columbia Canada, March 5-9, 2017